Leo Pharma files for marketing approval of tralokinumab in Japan
Pharmaceutical company Leo Pharma has announced it has filed a marketing authorization application with the Japanese health authority for the moderate-to-severe atopic eczema drug, tralokinumab.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
Leo Pharma has filed an application for marketing authorization of tralokinumab, the company’s treatment for patients with moderate-to-severe atopic eczema, in Japan, the company announces in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
